Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites
Identifieur interne : 003406 ( Main/Exploration ); précédent : 003405; suivant : 003407Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites
Auteurs : Cindy Woodland ; Shinya Ito ; Camille P. Granvil [États-Unis] ; Irving W. Wainer [États-Unis] ; Julia Klein ; Gideon Koren [Canada]Source :
- Life Sciences [ 0024-3205 ] ; 2000.
Abstract
Nephrotoxicity is a limiting factor in the use of ifosfamide in children. Despite the co-administration of uroprotective agents such as sodium 2-mercaptoethanesulfonate (mesna), ifosfamide chemotherapy is associated with nephropathy characterized by glomerular toxicity and Fanconi syndrome in many children treated with this drug. This is in distinction to cyclophosphamide, an analogue which differs solely by the position of a chloroethyl group, and which is not associated with nephrotoxicity. We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity. We found that in both pig renal cortical microsomes and whole human kidney microsomes incubated with 1 mM ifosfamide for 3 hr, 2 and 3 dechloroethylifosfamide (DCEI) were produced.Our study provides evidence that porcine and human kidney microsomes are capable of biotransforming ifosfamide to DCEI metabolites that are produced in equimolar amounts with chloroacetaldehyde, indicating that chloroacetaldehyde is locally produced by renal cells as a possible mechanism for nephrotoxicity.
Url:
DOI: 10.1016/S0024-3205(00)00915-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002397
- to stream Istex, to step Curation: 002397
- to stream Istex, to step Checkpoint: 001127
- to stream Main, to step Merge: 003934
- to stream Main, to step Curation: 003406
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites</title><author><name sortKey="Woodland, Cindy" sort="Woodland, Cindy" uniqKey="Woodland C" first="Cindy" last="Woodland">Cindy Woodland</name></author><author><name sortKey="Ito, Shinya" sort="Ito, Shinya" uniqKey="Ito S" first="Shinya" last="Ito">Shinya Ito</name></author><author><name sortKey="Granvil, Camille P" sort="Granvil, Camille P" uniqKey="Granvil C" first="Camille P." last="Granvil">Camille P. Granvil</name></author><author><name sortKey="Wainer, Irving W" sort="Wainer, Irving W" uniqKey="Wainer I" first="Irving W." last="Wainer">Irving W. Wainer</name></author><author><name sortKey="Klein, Julia" sort="Klein, Julia" uniqKey="Klein J" first="Julia" last="Klein">Julia Klein</name></author><author><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3A40DDB1D1D0E1FDA9D2F04A7FBFCCD87D2A0ED5</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0024-3205(00)00915-2</idno><idno type="url">https://api-v5.istex.fr/document/3A40DDB1D1D0E1FDA9D2F04A7FBFCCD87D2A0ED5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002397</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002397</idno><idno type="wicri:Area/Istex/Curation">002397</idno><idno type="wicri:Area/Istex/Checkpoint">001127</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001127</idno><idno type="wicri:doubleKey">0024-3205:2000:Woodland C:evidence:of:renal</idno><idno type="wicri:Area/Main/Merge">003934</idno><idno type="wicri:Area/Main/Curation">003406</idno><idno type="wicri:Area/Main/Exploration">003406</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites</title><author><name sortKey="Woodland, Cindy" sort="Woodland, Cindy" uniqKey="Woodland C" first="Cindy" last="Woodland">Cindy Woodland</name><affiliation><wicri:noCountry code="subField">1X8</wicri:noCountry></affiliation></author><author><name sortKey="Ito, Shinya" sort="Ito, Shinya" uniqKey="Ito S" first="Shinya" last="Ito">Shinya Ito</name><affiliation><wicri:noCountry code="subField">1X8</wicri:noCountry></affiliation></author><author><name sortKey="Granvil, Camille P" sort="Granvil, Camille P" uniqKey="Granvil C" first="Camille P." last="Granvil">Camille P. Granvil</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Georgetown University, Room C305 - Medical Dental Building, 3900 Reservoir Rd., N.W., Washington, DC 20007</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Wainer, Irving W" sort="Wainer, Irving W" uniqKey="Wainer I" first="Irving W." last="Wainer">Irving W. Wainer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Georgetown University, Room C305 - Medical Dental Building, 3900 Reservoir Rd., N.W., Washington, DC 20007</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Klein, Julia" sort="Klein, Julia" uniqKey="Klein J" first="Julia" last="Klein">Julia Klein</name><affiliation><wicri:noCountry code="subField">1X8</wicri:noCountry></affiliation></author><author><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><affiliation></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Life Sciences</title><title level="j" type="abbrev">LFS</title><idno type="ISSN">0024-3205</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">68</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="109">109</biblScope><biblScope unit="page" to="117">117</biblScope></imprint><idno type="ISSN">0024-3205</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0024-3205</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nephrotoxicity is a limiting factor in the use of ifosfamide in children. Despite the co-administration of uroprotective agents such as sodium 2-mercaptoethanesulfonate (mesna), ifosfamide chemotherapy is associated with nephropathy characterized by glomerular toxicity and Fanconi syndrome in many children treated with this drug. This is in distinction to cyclophosphamide, an analogue which differs solely by the position of a chloroethyl group, and which is not associated with nephrotoxicity. We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity. We found that in both pig renal cortical microsomes and whole human kidney microsomes incubated with 1 mM ifosfamide for 3 hr, 2 and 3 dechloroethylifosfamide (DCEI) were produced.Our study provides evidence that porcine and human kidney microsomes are capable of biotransforming ifosfamide to DCEI metabolites that are produced in equimolar amounts with chloroacetaldehyde, indicating that chloroacetaldehyde is locally produced by renal cells as a possible mechanism for nephrotoxicity.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>District de Columbia</li></region></list><tree><noCountry><name sortKey="Ito, Shinya" sort="Ito, Shinya" uniqKey="Ito S" first="Shinya" last="Ito">Shinya Ito</name><name sortKey="Klein, Julia" sort="Klein, Julia" uniqKey="Klein J" first="Julia" last="Klein">Julia Klein</name><name sortKey="Woodland, Cindy" sort="Woodland, Cindy" uniqKey="Woodland C" first="Cindy" last="Woodland">Cindy Woodland</name></noCountry><country name="États-Unis"><region name="District de Columbia"><name sortKey="Granvil, Camille P" sort="Granvil, Camille P" uniqKey="Granvil C" first="Camille P." last="Granvil">Camille P. Granvil</name></region><name sortKey="Wainer, Irving W" sort="Wainer, Irving W" uniqKey="Wainer I" first="Irving W." last="Wainer">Irving W. Wainer</name></country><country name="Canada"><noRegion><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003406 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003406 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3A40DDB1D1D0E1FDA9D2F04A7FBFCCD87D2A0ED5
|texte= Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites
}}
| This area was generated with Dilib version V0.6.29. |  |